Hanmi Pharm registers ‘Esomezol’
‘Esomezol,’ an acid reflux treatment developed by Hanmi Pharm, was registered at the U.S. Pharmacopeial(USP) for the first time as a Korean pharmaceutical company. Esomezol is the Korea’s first incrementally modified drug acquiring commercialization approval from the U.S. FDA.
Hanmi Pharm(CEO Jo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
